Drugs / RC198
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05867303 | Jun 2023 → Sep 2024 overdue | colorectal carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma +2 | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC198 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05867303 ↗ |
| Route | Subcutaneous | “RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.” NCT05867303 ↗ |